Illimaquinone, a selective inhibitor of the RNase H activity of human immunodeficiency virus type 1 reverse transcriptase
- 1 October 1990
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 34 (10) , 2009-2012
- https://doi.org/10.1128/aac.34.10.2009
Abstract
We studied the effect of the natural marine substance illimaquinone on the catalytic activities of reverse transcriptase from human immunodeficiency virus type 1. Illimaquinone inhibited the RNase H activity of the enzyme at concentrations of 5 to 10 .mu.g/ml, whereas RNA-dependent DNA polymerase and DNA-dependent DNA polymerase activities were considerably less susceptible to this inhibition. Two synthetic derivatives of illimaquinone, in which the 6''-hydroxyl group at the ortho position to one of the carbonyl groups of the quinone ring was modified, proved ineffective in inhibiting the human immunodeficiency virus type 1 reverse transcriptase RNase H function, suggesting involvement of the 6''-hydroxyl group in blocking the enzymatic activity.This publication has 27 references indexed in Scilit:
- HIV-1 Reverse Transcriptase Purified from a Recombinant Strain ofEscherichia coliAIDS Research and Human Retroviruses, 1990
- Comparison of inhibitory activities of various antiretroviral agents against particle-derived and recombinant human immunodeficiency virus type 1 reverse transcriptasesAntimicrobial Agents and Chemotherapy, 1989
- Biosynthesis and analysis of a genetically engineered HIV-1 reverse transcriptase/endonuclease polyprotein in Escherichia coliGene, 1988
- Expression in Escherichia coli of a Moloney murine leukemia virus reverse transcriptase whose structure closely resembles the viral enzymeGene, 1988
- AzidothymidineThe Journal of Infectious Diseases, 1988
- Strategies for antiviral therapy in AIDSNature, 1987
- Suramin in the treatment of AIDS: Mechanism of actionAntiviral Research, 1987
- Comparative inhibitory effects of suramin and other selected compounds on the infectivity and replication of human T‐cell lymphotropic virus (HTLV‐III)/lymphadenopathy‐associated virus (LAV)International Journal of Cancer, 1986
- ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEXThe Lancet, 1986
- ANTIMONIOTUNGSTATE (HPA 23) TREATMENT OF THREE PATIENTS WITH AIDS AND ONE WITH PRODROMEThe Lancet, 1985